0001140361-22-034882.txt : 20220927 0001140361-22-034882.hdr.sgml : 20220927 20220927190037 ACCESSION NUMBER: 0001140361-22-034882 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220923 FILED AS OF DATE: 20220927 DATE AS OF CHANGE: 20220927 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Venker Eric CENTRAL INDEX KEY: 0001801917 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40782 FILM NUMBER: 221272483 MAIL ADDRESS: STREET 1: C/O ROIVANT SCIENCES, INC. STREET 2: 320 WEST 37TH STREET, 6TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Roivant Sciences Ltd. CENTRAL INDEX KEY: 0001635088 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981173944 STATE OF INCORPORATION: D0 FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: CLARENDON HOUSE, 2 CHURCH STREET CITY: HAMILTON HM11 STATE: D0 ZIP: HM11 BUSINESS PHONE: 441-295-5950 MAIL ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 4 1 form4.xml X0306 4 2022-09-23 0001635088 Roivant Sciences Ltd. ROIV 0001801917 Venker Eric C/O ROIVANT SCIENCES LTD. 11-12 ST JAMES'S SQUARE, SUITE 1, 3RD FL LONDON X0 SW1Y 4LB UNITED KINGDOM true President & COO Common Shares 2022-09-23 4 S 0 17392 3.07 D 1065772 D Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker 2022-09-27